Key facts
- Batea Oncology’s last known valuation is $3.1M (Nov 2025).
- It has raised $880K; the latest was Equity Crowdfunding ($880K) in Nov 2025.
- Notable investors include XesGalicia, Unirisco.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Batea Oncology
- ·The full record, as it builds
Funding rounds
No funding rounds for Batea Oncology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Batea Oncology
Developer of new therapeutic techniques to tackle aggressive cancers with low survival, aimed at improving treatment and patient survival rates. The company offers a class III medical device implemented during tumor surgery, enabling medical practitioners to trap residual tumor cells and sensitize them to the radiotherapy process.
- Sector
- Healthcare
- HQ
- Santiago de Compostela, Spain
- Founded
- 2024
- Employees
- 7
- Website
- bateaoncology.com/
- Ownership
- Privately Held (backing)
Batea Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Batea Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Batea Oncology in its N-PORT filings yet. We sweep new filings monthly.